Progesterone Suppository
Status
FDA-approved. FDA-approved labeling exists for vaginal progesterone products including gel and inserts for luteal phase support in assisted reproductive technology and for secondary amenorrhoea. Compounded suppositories are not FDA-reviewed.
What it is
A vaginal progesterone form used in fertility and hormone care.
What published research measured
Progesterone delivered vaginally or rectally. The pharmacological rationale is well supported and specific: vaginal administration produces markedly higher progesterone concentrations in uterine tissue than serum concentrations would predict, an effect described as first uterine pass, while avoiding the hepatic metabolism that generates the sedating metabolites of oral dosing. This is why vaginal progesterone is standard in assisted reproduction luteal support, where randomized evidence is substantial, and why randomized trials support it for reducing preterm birth risk in women with a short cervix. Because serum concentrations understate tissue exposure, blood testing is a poor guide to adequacy on this route. Compounded suppositories vary in base and release characteristics.
Source
Randomized trials of vaginal progesterone for luteal support and preterm birth prevention
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.